Everything below concerns peptide hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Matthew Collins, is a professor at the University of Copenhagen, formerly as a Niels Bohr professor, and also holds a McDonald Chair in Palaeoproteomics at the University of Cambridge. Prior to joining Cambridge he was professor of biomolecular archaeology at the University of York where he founded BioArCh, a collaboration between the departments of biology, chemistry and archaeology (BioArCh: Biology Archaeology, Chemistry). His research focuses on the persistence of proteins in ancient samples, using modelling to explore the racemization of amino acids and thermal history to predict the survival of DNA and other molecules Using a combination of approaches (including immunology and protein mass spectrometry) his research detects and interprets protein remnants in archaeological and fossil remains. With former PhD student Mike Buckley he developed ZooMS (zooarchaeology by mass spectrometry) a way to rapidly identify bone and other collagen based materials using peptide mass fingerprinting. In 2022 Collins received the Pomerance Award for Scientific Contributions to Archaeology from the Archaeological Institute of America. Collins was elected a Fellow of the British Academy in 2014 in 2014, the Royal Danish Academy of Sciences and Letters in 2021 and the Royal Swedish Academy of Sciences in 2022.
Perhaps the earliest of these sutras, the Aṣṭasāhasrikā Prajñāpāramitā, contains a passage which describes the suchness (tathatā) of dharmas using various terms including shūnyatā, cessation (nirodha) and unarisen (anutpāda). Most famously, the Heart Sutra states:Sariputra, in that way, all phenomena are empty, that is, without characteristic, unproduced, unceased, stainless, not stainless, undiminished, unfilled.The Heart Sutra also negates the 12 links of dependent origination: "There is no ignorance, no extinction of ignorance, up to and including no aging and death and no extinction of aging and death." Some Mahāyāna sūtras present the insight into the non-arisen nature of dharmas as a great achievement of bodhisattvas.
ImmTACs (Immune mobilising monoclonal T-cell receptors Against Cancer) are a class of bispecific biological drug being investigated for the treatment of cancer and viral infections which combines engineered cancer-recognizing TCRs with immune activating complexes. ImmTACs target cancerous or virally infected cells through binding human leukocyte antigen (HLA) presented peptide antigens and redirect the host's cytotoxic T cells to recognise and kill them. ImmTACs are fusion proteins that combine an engineered T Cell Receptor (TCR) based targeting system with a single chain antibody fragment (scFv) effector function. TCRs, like antibodies, constitute an important antigen recognition system within the immune system; but, whereas antibodies are restricted to targeting cell surface or secreted proteins TCRs can recognise peptides derived from intracellular targets presented by human leukocyte antigen (HLA). Naturally occurring TCRs are low affinity (0.18-387 micromolar range) 2-chain membrane receptors expressed on the surface of T cells. To produce stable, soluble, high affinity TCRs capable of being used as diagnostics and therapeutics the two TCR protein chains are stabilised through the introduction of a novel disulphide bond between the 2 constant domains and the affinity increased 1-5 million fold to low picomolar values through phage display affinity maturation. To provide the soluble, affinity enhanced TCR with a biological effector function the beta chain of the TCR is fused to an scFv antibody fragment specific for the CD3 T cell co-receptor, creating an ImmTAC.
An increase in the expression of Group 2 mGluRs, which could arise from a chronic under stimulation of these receptors, has been associated with schizophrenia. An increase in levels of system Xc- has also been found in postmortem schizophrenia patients, indicating that there may have been a decrease in net function of these receptors as well, leading to greater expression. It has been observed that Schizophrenia patients have a decreased level of glutathione in their prefrontal cortex, further supporting the conclusion that system Xc- may not be functioning properly. Clinical trials have shown therapeutic potential for N-acetylcysteine in treating schizophrenia. Again, changes in EAATs due to disruptions in Glutamate homeostasis may also be involved. Recent study showed that mRNA expression levels of both SLC3A2 and SLC7A11 in WBCs of schizophrenia patients are lower than that of healthy individuals. The finding supports the hypo-glutamatergic neurotransmission hypothesis in schizophrenia.
Sources: en.wikipedia.org
In Season 6, while in labor, Jackie is shocked when Bev reveals Jackie's birth name is actually Marjorie; the family began calling her Jackie because Roseanne, unable to pronounce the name Marjorie, instead called her baby sister "my Jackie". But in Season 10, Jackie introduces herself to Andrea, the woman looking to hire Becky as her surrogate, as Jacqueline. Despite Jackie's apparent flightiness in the early episodes, she is actually the backbone of the Conner/Harris family in many ways, as Roseanne admits in the last episode of Season 9, and which also reveals that Jackie, not Bev, had come out as a lesbian during the final season and that Roseanne knew, but had just always pictured her with a man.
== Function == CART is a neuropeptide that produces similar behavior in animals as cocaine and amphetamine, but conversely blocks the effects of cocaine when they are co-administered. The peptide is found in several areas, among them the ventral tegmental area (VTA) of the brain. When CART was injected into rat VTA, increased locomotor activity was seen, which is one of the signs of "central stimulation" caused by psychostimulants, such as cocaine and amphetamine. The same rats also tended to return to the place where they were injected. This is called conditioned place preference and is also seen after injection of cocaine. CART peptides, in particular, CART(55–102), seem to have an important function in the regulation of energy homeostasis and interact with several hypothalamic appetite circuits. CART expression is regulated by several peripheral peptide hormones involved in appetite regulation, including leptin, cholecystokinin and ghrelin, with CART and cholecystokinin having synergistic effects on appetite regulation. CART is released in response to repeated dopamine release in the nucleus accumbens, and may regulate the activity of neurons in this area. CART production is upregulated by CREB, a protein thought to be involved with the development of drug addiction, and CART may be an important therapeutic target in the treatment of stimulant abuse.
A Jarisch–Herxheimer reaction is a sudden and typically transient reaction that may occur within 24 hours of being administered antibiotics for an infection by a spirochete, including syphilis, leptospirosis, Lyme disease, and relapsing fever. Signs and symptoms include fever, chills, shivers, feeling sick, headache, fast heart beat, low blood pressure, breathing fast, flushing of skin, muscle aches, and worsening of skin lesions. It may sometimes be mistaken as an allergy to the antibiotic. Jarisch–Herxheimer reactions are usually self-limiting but severe presentations can be life-threatening if they cause a significant drop in blood pressure and cause acute end-organ injury, eventually leading to multi-organ failure.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.